Advent offers €1.919bn for Sanofi’s Zentiva

Private equity Advent International has announced today in a press release that it is in exclusive talks with Sanofi to acquire Zentiva, the French company’s arm that markets generics all over Europe. Advent has offered Sanofi €1.919bn. Advent International, which has €35bn in assets, has beaten the investor BC Partners, its competitor, which has recently pulled out of the race to Zentiva, renouncing to submit its binding offer.

(Sources: Sanofi, Advent International)